Emergent BioSolutions Inc.
EBS
$8.07
-$0.06-0.74%
NYSE
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 127.60% | 136.35% | 123.76% | 76.72% | 74.94% |
| Total Depreciation and Amortization | -11.95% | -12.54% | -11.14% | -10.22% | -13.03% |
| Total Amortization of Deferred Charges | 32.43% | -13.76% | -99.14% | -89.71% | -65.26% |
| Total Other Non-Cash Items | -21.62% | -51.52% | -109.46% | -86.05% | -90.71% |
| Change in Net Operating Assets | -125.25% | -187.50% | -119.68% | 151.25% | 226.17% |
| Cash from Operations | 190.63% | -92.38% | 119.48% | 229.68% | 128.45% |
| Capital Expenditure | 39.74% | 64.42% | 64.47% | 66.81% | 55.62% |
| Sale of Property, Plant, and Equipment | 383.54% | 406.58% | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -100.00% | -- | -59.22% | -59.22% |
| Other Investing Activities | 50.00% | -- | 1,290.48% | 973.02% | 576.19% |
| Cash from Investing | -44.57% | 19.60% | 575.49% | -9.74% | -41.03% |
| Total Debt Issued | -- | -100.00% | 157.65% | 234.29% | 1,320.00% |
| Total Debt Repaid | 76.68% | 98.62% | -222.15% | 16.03% | 14.38% |
| Issuance of Common Stock | -79.63% | -83.18% | 678.57% | 6.86% | 5.88% |
| Repurchase of Common Stock | -2,091.67% | -1,610.00% | -925.00% | -62.50% | 52.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 100.00% | 179.66% | -- | -- |
| Cash from Financing | 28.11% | 88.05% | -284.74% | 52.30% | 64.53% |
| Foreign Exchange rate Adjustments | -- | 106.67% | 175.00% | 30.00% | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1,796.72% | 35.28% | 1,236.36% | 121.01% | 98.85% |